jw van zyl incMarket entry and partnerships
The non-binding MoU as a market-entry instrument: what it does and does not do
A government-level cooperation agreement signed as an expressly non-binding MoU — a common opening instrument in African market entry, and a common source of internal misalignment about what has actually been agreed.
Verified development
On 14 May 2026 Bayer and the Government of Rwanda signed a strategic cooperation agreement in Kigali, witnessed by the EU Delegation to Rwanda.
Bayer states that the purpose is to facilitate access to products from its pharmaceutical portfolio in support of national public health priorities, with potential regional expansion across Sub-Saharan Africa.
The announcement expressly records that the MoU is non-binding and exploratory, and that any future activities are subject to due diligence, regulatory approvals and mutually agreed definitive contracts.
No local manufacturing commitment, product-registration commitment or therapeutic area is stated in the announcement.
Why it matters
Instruments of this kind are read very differently by the teams that have to act on them. Commercial and market-access teams frequently begin planning to a timeline the instrument does not support, and the resulting pressure lands on whoever has to paper definitive agreements against a date that was never negotiated.
Legal and commercial implications
- A government-level MoU is a real commercial instrument and it is routinely misread inside the organisations that sign it. It creates political alignment and a sequencing expectation. It does not create supply obligations, pricing commitments, registration timelines or a route to market.
- The legal work sits in the gap between the instrument and the definitive contracts. That gap is where the operating structure gets decided: which entity contracts, who holds the marketing authorisation, who imports, who carries product liability, and which body actually procures.
- Even an expressly non-binding instrument can carry binding provisions — confidentiality, exclusivity, governing law, dispute resolution and, occasionally, an obligation to negotiate in good faith. Those survive the non-binding framing and are the clauses most often skimmed.
- Where an arrangement contemplates regional expansion, the South African leg is a separate exercise. The regulatory pathway, the local operating structure and the responsibility allocation do not transfer from one African jurisdiction to another.
Questions a counterparty's own team will need to answer
- Which provisions of the instrument are in fact binding, and has that been confirmed in writing to the commercial team rather than assumed?
- Which entity will contract at definitive-agreement stage, and does it have the standing and authorisations the arrangement requires?
- Is there an exclusivity or good-faith negotiation obligation that constrains parallel discussions in the same territory?
- If the arrangement extends to South Africa, has the local operating structure, marketing-authorisation holder and responsibility allocation been scoped as its own workstream?
Sources